ILIU / Interleukin Genetics, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Interleukin Genetics FORM 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-32715 Interleukin Genetics, Inc. (Exact Name of Registrant as specified

Interleukin Genetics DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Interleukin Genetics FORM 25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-32715 Interleukin Genetics, Inc. OTCQB (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 135 Beaver Street Wal

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 21) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2017 Interleukin Genetics, Inc.

Interleukin Genetics to Wind-Up and Pursue a Plan of Liquidation Will begin process of delisting and deregistering

EX-99.1 2 v471353ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics to Wind-Up and Pursue a Plan of Liquidation Will begin process of delisting and deregistering WALTHAM, Mass, - July 24, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the adoption of a plan to wind-up and liquidate the Company subject to shareholder approval via a Proxy Statement with a special meeting of t

Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce

Exhibit 99.1 Interleukin Genetics To Explore Strategic Alternatives, Reduce Workforce WALTHAM, Mass. ? July 3, 2017 ? Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that it will pursue strategic alternatives for the Company and will reduce the Company?s workforce by five employees (63%) as part of a plan to reduce operating costs. ?While this decision was extremely difficult, it is impor

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition, Other Events

8-K 1 v4702338k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 3, 2017 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32715 94-3

ILIU / Interleukin Genetics, Inc. 10-Q (Quarterly Report)

10-Q 1 v46612810q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

ILIU / Interleukin Genetics, Inc. FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEU

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.2.3 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this Amendment No. 2 to Annual Report on Form 10-K/A of Interleukin Genetics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.1.3 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this Amendment No. 2 to Annual Report on Form 10-K/A of Interleukin Genetics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.1.2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Interleukin Genetics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,

ILIU / Interleukin Genetics, Inc. FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEU

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.2.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Interleukin Genetics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m

ILIU / Interleukin Genetics, Inc. 10-K (Annual Report)

10-K 1 v46406310k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 I

Subordinated Convertible Promissory Note

Exhibit 4.12 NEITHER THIS NOTE, NOR THE SHARES OF COMMON STOCK FOR WHICH IT IS CONVERTIBLE, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND NEITHER MAY BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE ACT AND SUCH LAWS OR (1) REGISTRATION UNDER APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED

SUBSCRIPTION AGREEMENT

Exhibit 10.21 EXECUTION VERSION SUBSCRIPTION AGREEMENT Subject to the terms and conditions set forth in this Subscription Agreement, dated as of April 17, 2017 (this “Agreement”), each of the undersigned (each, a “Subscriber” and collectively, the “Subscribers”) hereby offers to purchase from Interleukin Genetics, a Delaware corporation (the “Company”), a subordinated convertible promissory note i

INTERLEUKIN GENETICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

Exhibit 4.11 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A

INTERLEUKIN GENETICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

Exhibit 4.10 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A

SECOND amendment of VENTURE LOAN AND SECURITY AGREEMENT

EX-10.18X3 5 v464063ex10-18x3.htm EXHIBIT 10.18.3 Exhibit 10.18.3 SECOND amendment of VENTURE LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of April 17, 2017, is entered into by and among INTERLEUKIN GENETICS, INC. (“Borrower”) and HORIZON CREDIT II LLC, as assignee of Horizon Technology Finance Corporation (“Lender”). RECITAL

Interleukin Genetics NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report o

122,585,504 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-213595 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated September 27, 2016 122,585,504 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated September 27, 2016, relating to the offering and resale by the selling stockholders of up to 122,585,504 shares of our common stock. We will not receive any proceeds from the sa

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 27, 2017 Interleukin Genetics, Inc.

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 20) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 22, 2016 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

424B3 1 v453117424b3.htm FORM 424(B)(3) Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not

122,585,504 SHARES OF COMMON STOCK

424B3 1 v453116424b3.htm FORM 424(B)(3) Filed pursuant to Rule 424(b)(3) Registration No. 333-213595 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated September 27, 2016 122,585,504 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated September 27, 2016, relating to the offering and resale by the selling stockholders of up to 122,585,504 shares of our common stock. We w

Interleukin Genetics FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN

SERVICES AGREEMENT

Exhibit 10.1 CONFIDENTIAL EXECUTION VERSION SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?) is entered into effective as of July 1, 2016, by and between Interleukin Genetics, Inc., with an address of 135 Beaver Street, Waltham, MA 02452 (?INTERLEUKIN?), and Alticor Inc., with an address of 7575 Fulton Street East, Ada, MI 49355, as plan sponsor and plan administrator for the Amway Em

135 Beaver Street • Waltham, MA 02452 • Tel: 781-398-0700 • Fax: 781-398-0720

Exhibit 10.4 May 19, 2016 Stephan Toutain Re: Offer Letter of Employment Dear Stephan: I am pleased to provide you with this offer letter agreement (the "Letter Agreement"), which provides the terms and conditions of your anticipated employment by Interleukin Genetics, Inc. ("Interleukin"), which would become effective as of the Start Date (as defined below). We hope that you choose to join the In

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 20, 2016 Interleukin Genetics, Inc.

ILIU / Interleukin Genetics, Inc. / Delta Dental Plan of Michigan, Inc. - SC 13D AMENDMENT NO. 4 Activist Investment

SC 13D Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Jonathan S. Groat Delta Dental Plan of Michigan, Inc. 4100 Okemos Road Okemos, MI 48864

Interleukin Genetics FORM RW

September 30, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Third Amendment to Commercial Lease

Exhibit 10.1 Third Amendment to Commercial Lease The Parties hereto, Clematis LLC, (?LESSOR?) and Interleukin Genetics, Inc., (?LESSEE?) are Parties under a certain Commercial Lease (?Lease Agreement?) dated February 13, 2004, a First Amendment to Commercial Lease (?First Amendment?) dated November 18, 2008, and a Second Amendment to Commercial Lease (?Second Amendment?) dated February 7, 2014, fo

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 27, 2016 Interleukin Genetics, Inc.

122,585,504 SHARES OF COMMON STOCK

File pursuant to Rule 424(b)(3) Registration No. 333-213595 PROSPECTUS 122,585,504 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 122,585,504 shares of our common stock. These shares consist of (1) 56,262,571 issued and outstanding

Interleukin Genetics ESP

INTERLEUKIN GENETICS, INC. 135 Beaver Street Waltham, Massachusetts 02452 September 23, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Josh Samples Re: Interleukin Genetics, Inc. Registration Statement on Form S-1 File No. 333-213595 Dear Mr. Samples: With respect to the above-referenced Registration Statement

Interleukin Genetics S-1

As filed with the Securities and Exchange Commission on September 12, 2016 Registration Statement No.

Interleukin Genetics DEFA14A

DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Interleukin Genetics DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Interleukin Genetics PRER14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Interleukin Genetics ESP

Brian P. Keane | 617 348 3093 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com September 7, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik Erin Jaskot Re: Interleukin Genetics, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 30, 2016 F

Interleukin Genetics PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

INTERLEUKIN GENETICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE AP

INTERLEUKIN GENETICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK

Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE AP

FIRST amendment of VENTURE LOAN AND SECURITY AGREEMENT

EX-10.1 3 v447798ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST amendment of VENTURE LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of August 25, 2016, is entered into by and among INTERLEUKIN GENETICS, INC. (“Borrower”) and HORIZON CREDIT II LLC, as assignee of Horizon Technology Finance Corporation (“Lender”). RECITALS A. Borrower

FIRST amendment of VENTURE LOAN AND SECURITY AGREEMENT

EX-10.1 3 v447798ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST amendment of VENTURE LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of August 25, 2016, is entered into by and among INTERLEUKIN GENETICS, INC. (“Borrower”) and HORIZON CREDIT II LLC, as assignee of Horizon Technology Finance Corporation (“Lender”). RECITALS A. Borrower

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 v4477988k.htm FORM 8- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 25, 2016 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 v4477988k.htm FORM 8- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 25, 2016 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 19) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 19) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Keane, Garrett Winslow, Sarita Malakar, Anne Leland and Jacquelyn Cannata, each of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the under

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

Interleukin Genetics FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN GENE

Interleukin Genetics FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN GENE

ILIU / Interleukin Genetics, Inc. / Growth Equity Opportunities Fund III, LLC - INTERLEUKIN GENETICS, INC. - 13DA Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 458738101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, A

ILIU / Interleukin Genetics, Inc. / BAY CITY CAPITAL LLC - SC 13D AMENDMENT NO. 3 Activist Investment

SC 13D Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Susan Vuong Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 S

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

Interleukin Genetics Strengthens Commercial Leadership with Key Appointments Stephan Toutain appointed Chief Commercial Officer and Mary Hiter appointed Director of Marketing

EX-99.1 2 v445987ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics Strengthens Commercial Leadership with Key Appointments Stephan Toutain appointed Chief Commercial Officer and Mary Hiter appointed Director of Marketing WALTHAM, Mass. – August 3, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life science company focused on the genetics of chronic inflammation, today announced the app

Current Report

8-K 1 v4459878k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 3, 2016 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

COMMON STOCK PURCHASE WARRANT Interleukin Genetics, Inc.

EX-4.1 2 v445526ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD E

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 v4455268k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2016 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-

INTERLEUKIN GENETICS, INC. ANNOUNCES $5.6 MILLION PRIVATE PLACEMENT FINANCING

Exhibit 99.1 INTERLEUKIN GENETICS, INC. ANNOUNCES $5.6 MILLION PRIVATE PLACEMENT FINANCING WALTHAM, MA ? August 1, 2016 ? Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that it has entered into an agreement with various accredited and institutional in

SECURITIES PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. The Purchasers Identified on Schedule I Hereto July 29, 2016 Table of Contents

Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. and The Purchasers Identified on Schedule I Hereto July 29, 2016 Table of Contents Page 1. PURCHASE AND SALE 1 (a) Authorization of Shares 1 (b) Purchase of Shares and Warrants 1 2. CLOSING 1 (a) The Closing 1 (b) Form of Payment 2 (c) Conditions to the Purchaser?s Obligation to Purchase on the Clos

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 29, 2016, between Interleukin Genetics, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the S

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

Interleukin Genetics To Offer Its Innovative Inflammation Management Program To Amway Employees Interleukin Genetics To Provide Integrated Program of Genetic Risk Assessment and Patient Engagement To Support Better Health

EX-99.1 2 v444073ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics To Offer Its Innovative Inflammation Management Program To Amway Employees Interleukin Genetics To Provide Integrated Program of Genetic Risk Assessment and Patient Engagement To Support Better Health WALTHAM, MA – July 12, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of c

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 11, 2016 Interleukin Genetics, Inc.

I N T E R L E U K I N G E N E T I C S Page 1 Transforming Inflammation Management Making Genetic Insights Actionable Interleukin Genetics Investor Overview June 2016 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.

I N T E R L E U K I N G E N E T I C S Page 1 Transforming Inflammation Management Making Genetic Insights Actionable Interleukin Genetics Investor Overview June 2016 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.

Interleukin Genetics FORM S-1/A

As filed with the Securities and Exchange Commission on June 7, 2016 Registration Statement No.

Interleukin Genetics S-1/A

S-1/A 1 v441555s1a.htm S-1/A As filed with the Securities and Exchange Commission on June 3, 2016 Registration Statement No. 333-211361 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No 1 To FORM S-1 REGISTRATION STATEMENT under the SECURITIES ACT OF 1933 INTERLEUKIN GENETICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2835 94-3123681 (S

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated April 14, 2016 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated April 14, 2016 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated April 14, 2016, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

Interleukin Genetics FORM S-1

As filed with the Securities and Exchange Commission on May 13, 2016 Registration Statement No.

Interleukin Genetics FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN GEN

Interleukin Genetics FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.2.1 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this annual report on Form 10-K of Interleukin Genetics, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.1.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002 I, certify that: 1. I have reviewed this annual report on Form 10-K of Interleukin Genetics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 102,781,654 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 102,781,654 shares of our common stock. These shares consist of (1) 50,099,700 issued and outstanding shares and

120,408,197 SHARES OF COMMON STOCK

Filed Pursuant to Rule 424(b)(3) Registration No. 333-189749 120,408,197 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 120,408,197 shares of our common stock. These shares consist of 85,326,230 issued and outstanding shares and 35,

Interleukin Genetics ESP

INTERLEUKIN GENETICS, INC. 135 Beaver Street Waltham, Massachusetts 02452 April 12, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Gershon Re: Interleukin Genetics, Inc. Post-Effective Amendment No. 3 to Registration Statement on Form S-1 Filed March 23, 2016 File No. 333-189749 Dear Mr. Gershon: With r

Interleukin Genetics ESP

INTERLEUKIN GENETICS, INC. 135 Beaver Street Waltham, Massachusetts 02452 April 12, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Gershon Re: Interleukin Genetics, Inc. Post-Effective Amendment No. 1 to Registration Statement on Form S-1 Filed March 23, 2016 File No. 333-201908 Dear Mr. Gershon: With r

Interleukin Genetics POS AM

As filed with the Securities and Exchange Commission on March 22, 2016 Registration Statement No.

Interleukin Genetics POST -EFFECTIVE AMENDMENT

As filed with the Securities and Exchange Commission on March 22, 2016 Registration Statement No.

SERVICES AGREEMENT

EX-10.23 2 v434040ex10-23.htm EXHIBIT 10.23 Exhibit 10.23 SERVICES AGREEMENT THIS SERVICES AGREEMENT (this “Agreement”) is entered into effective as of February 1, 2016, by and between Interleukin Genetics, Inc., a Delaware corporation with an address of 135 Beaver Street, Waltham, MA 02452 (“INTERLEUKIN”), and Metagenics, Inc., a Delaware corporation with an address of 25 Enterprise, Suite 200, A

Interleukin Genetics 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN GENETICS, INC. (

Interleukin Genetics and Metagenics Enter into Agreement to Incorporate PerioPredict® into Metagenics’ Employee Benefit Plan

EX-99.1 2 v432269ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics and Metagenics Enter into Agreement to Incorporate PerioPredict® into Metagenics’ Employee Benefit Plan WALTHAM, MA – February 18, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, and Met

Interleukin Genetics 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 17, 2016 Interleukin Genetics, Inc.

JOINT FILING AGREEMENT

CUSIP No. 458738101 SCHEDULE 13G EXHIBIT B JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other persons signatory below of a statement on Schedule 13G or any amendments thereto, with respect to the Common Stock of Interleuken Genetics, Inc.. and that this Agreement be included

ILIU / Interleukin Genetics, Inc. / Merlin BioMed Private Equity Advisors, L.L.C. - AMENDMENT NO. 3 Passive Investment

SC 13G/A 1 ss1399470sc13ga.htm AMENDMENT NO. 3 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No 3 )* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 458738101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the approp

[Signature Page to Follow]

EX-10.1 2 v426972ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 December 14, 2015 Kenneth S. Kornman 920 Centre Street Newton, MA 02459 Re: Agreement of Employment Dear Ken: I am pleased to provide you with this agreement (the “Letter Agreement”), which provides the terms and conditions of your continued employment by Interleukin Genetics, Inc. (“Interleukin”). 1. Commencement Date. This Letter Agreement sh

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 v4269728k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2015 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorpora

INTERLEUKIN GENETICS, INC. April 6, 2015

EXHIBIT 99.2 Non-Qualified Stock Option Agreement 11,622,279 Shares of Common Stock, $.001 par value per share INTERLEUKIN GENETICS, INC. April 6, 2015 As of April 6, 2015 (the ?Grant Date?), Interleukin Genetics, Inc. (the ?Company?), a Delaware corporation, grants to Mark Carbeau (the ?Participant?) the right and option (the ?Option?) to purchase up to 11,622,279 shares of the common stock, $.00

Interleukin Genetics S-8

As filed with the Securities and Exchange Commission on November 18, 2015 Registration No.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated March 31, 2015 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 31, 2015, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated March 27, 2015 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 27, 2015, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated March 27, 2015 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 27, 2015, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated March 31, 2015 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 31, 2015, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

INTERLEUKIN GENETICS, INC. 2013 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN1

Exhibit 10.1 INTERLEUKIN GENETICS, INC. 2013 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN1 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Interleukin Genetics, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has

CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION INTERLEUKIN GENETICS, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF INTERLEUKIN GENETICS, INC. It is hereby certified that: FIRST: The name of the corporation is Interleukin Genetics, Inc. (the ?Corporation?). SECOND: The Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on March 28, 2000. A Restated Certificate of Incorpora

Interleukin Genetics FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2015 Interleukin Genetics, Inc.

Interleukin Genetics DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Interleukin Genetics FORM DEFA14A

DEFA14A 1 v412559defa14a.htm FORM DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party o

Interleukin Genetics ESP

Brian P. Keane | 617 348 3093 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com June 4, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alla Berenshteyn Re: Interleukin Genetics, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 26, 2015 File No. 001-32

Interleukin Genetics PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated March 31, 2015 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 31, 2015, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

424B3 1 v410884424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated March 27, 2015 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 27, 2015, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive a

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated March 27, 2015 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 27, 2015, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated March 31, 2015 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 31, 2015, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated March 27, 2015 102,781,654 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 27, 2015, relating to the offering and resale by the selling stockholders of up to 102,781,654 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

424B3 1 v407151424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated March 31, 2015 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated March 31, 2015, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive a

Interleukin Genetics Appoints Mark B. Carbeau as CEO

EX-99.1 5 v406819ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics Appoints Mark B. Carbeau as CEO WALTHAM, MA, April 7, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief

THIRD AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT

Exhibit 10.2 THIRD AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT This Third Amendment (the ?Amendment?) to the Common Stock Purchase Agreement, dated May 17, 2013 (as on March 31, 2014 and May 30, 2014), by and among Interleukin Genetics, Inc., a Delaware corporation (the ?Company?), and the Purchasers identified on Schedule I thereto (the ?Purchase Agreement?), is made as of April 6, 2015, by

FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT

Exhibit 10.3 FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT This First Amendment (the ?Amendment?) to the Securities Purchase Agreement, dated December 23, 2014, by and among Interleukin Genetics, Inc., a Delaware corporation (the ?Company?), and the Purchasers identified on Schedule I thereto (the ?Purchase Agreement?), is made as of April 6, 2015, by and among the Company, the Purchasers s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2015 Interleukin Genetics, Inc.

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), made and entered into this 6th day of April, 2015 (the ?Effective Date?), by and between Interleukin Genetics, Inc, a Delaware corporation (?Company?), and Mark Carbeau (?Executive?). WHEREAS, Company wishes to employ Executive as its Chief Executive Officer; WHEREAS, Executive represents that Executive posses

POWER OF ATTORNEY

Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Brian Keane, Esther Cho, Anne Leland and Jacquelyn Cannata, each of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, forms and aut

120,408,197 SHARES OF COMMON STOCK

424B3 1 v406207424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS 120,408,197 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 120,408,197 shares of our common stock. These shares consist of 85,326

102,781,654 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-201908 PROSPECTUS 102,781,654 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 102,781,654 shares of our common stock. These shares consist of (1) 50,099,700 issued and outstanding

Interleukin Genetics ESP

INTERLEUKIN GENETICS, INC. 135 Beaver Street Waltham, Massachusetts 02452 March 25, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Johnny Gharib Re: Interleukin Genetics, Inc. Registration Statement on Form S-1 File No. 333-201908 Dear Mr. Gharib: With respect to the above-referenced Registration Statement on F

Interleukin Genetics POST-EFFECTIVE AMENDMENT NO. 2

As filed with the Securities and Exchange Commission on March 24, 2015 Registration Statement No.

Interleukin Genetics S-1/A

As filed with the Securities and Exchange Commission on March 24, 2015 Registration Statement No.

ILIU / Interleukin Genetics, Inc. / Merlin BioMed Private Equity Advisors, L.L.C. - AMENDMENT NO 2 Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No 2 )* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 458738101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

JOINT FILING AGREEMENT

EXHIBIT B JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other persons signatory below of a statement on Schedule 13G or any amendments thereto, with respect to the Common Stock of Interleuken Genetics, Inc.

COMMON STOCK PURCHASE WARRANT

EXHIBIT 4.5 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIE

ILIU / Interleukin Genetics, Inc. S-1 - Registration Statement - S-1

As filed with the Securities and Exchange Commission on February 6, 2015 Registration Statement No.

CONSULTING AGREEMENT

Exhibit 10.13 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of September 8, 2014 (the “Effective Date”), by and between Interleukin Genetics, Inc., a Delaware corporation, with its principal place of business being 135 Beaver Street, Waltham, MA 02452 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principa

ILIU / Interleukin Genetics, Inc. / Delta Dental Plan of Michigan, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Jonathan S. Groat Delta Dental Plan of Michigan, Inc. 4100 Okemos Road Okemos, MI 48864 (517) 347-5451

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 18) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

ILIU / Interleukin Genetics, Inc. / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, CA

ILIU / Interleukin Genetics, Inc. / Growth Equity Opportunities Fund III, LLC - INTERLEUKIN GENETICS Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 458738101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, A

ILIU / Interleukin Genetics, Inc. / BAY CITY CAPITAL LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, CA

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated May 29, 2014 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated May 29, 2014, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of these

REGISTRATION RIGHTS AGREEMENT

EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 23, 2014, between Interleukin Genetics, Inc., a Delaware corporation (the “Company”), each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”), and BTIG, LLC, a broker-dealer registered with the Fina

COMMON STOCK PURCHASE WARRANT Interleukin Genetics, Inc.

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

VENTURE LOAN AND SECURITY AGREEMENT

EXHIBIT 10.3 VENTURE LOAN AND SECURITY AGREEMENT Dated as of December 23, 2014 by and among HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation 312 Farmington Avenue Farmington, CT 06032 as Lender And INTERLEUKIN GENETICS, INC., a Delaware corporation 135 Beaver Street Lexington, MA 02452 as Borrower Loan A Commitment Amount: $5,000,000 Loan A Commitment Termination Date: December 23, 2

INTERLEUKIN GENETICS RAISES $10 MILLION IN FINANCINGS $5.0 million equity private placement and $5.0 million debt financing

EXHIBIT 99.1 Contacts: Media: Investors: David Pitts Susan Kim Argot Partners Argot Partners 212-600-1902 212-600-1902 [email protected] [email protected] INTERLEUKIN GENETICS RAISES $10 MILLION IN FINANCINGS $5.0 million equity private placement and $5.0 million debt financing WALTHAM, MA – December 23, 2014 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has entere

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 23, 2014 Interleukin Genetics, Inc.

SECURITIES PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. The Purchasers Identified on Schedule I Hereto December 23, 2014 Table of Contents

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. and The Purchasers Identified on Schedule I Hereto December 23, 2014 Table of Contents Page 1. PURCHASE AND SALE 1 (a) Authorization of Shares 1 (b) Purchase of Shares and Warrants 1 2. CLOSING 1 (a) The Closing 1 (b) Form of Payment 2 (c) Conditions to the Purchaser’s Obligation to Purchase on the Closing Date 2

INTERLEUKIN GENETICS, INC. WARRANT TO PURCHASE 2,492,523 SHARES OF COMMON STOCK

EXHIBIT 4.2 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE AP

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated May 29, 2014 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated May 29, 2014, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of these

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 8, 2014 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated May 29, 2014 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated May 29, 2014, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of these

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2014 Interleukin Genetics, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 23, 2014 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated May 29, 2014 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated May 29, 2014, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of these

- FORM DEFA 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated May 29, 2014 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated May 29, 2014, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of these

SECOND AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT

EX-10.1 2 v380163ex10-1.htm EXHIBIT10.1 SECOND AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT This Second Amendment (the “Amendment”) to the Common Stock Purchase Agreement, dated May 17, 2013 (as first amended on March 31, 2014), by and among Interleukin Genetics, Inc., a Delaware corporation (the “Company”), and the Purchasers identified on Schedule I thereto (the “Purchase Agreement”), is mad

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 30, 2014 Interleukin Genetics, Inc.

PROSPECTUS 120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS 120,408,197 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 120,408,197 shares of our common stock. These shares consist of 85,326,230 issued and outstanding sha

- FORM POS AM

As filed with the Securities and Exchange Commission on May 16, 2014 Registration Statement No.

March 25, 2014

EX-99.6 Exhibit 99.6 www.deltadentalmi.com March 25, 2014 Interleukin Genetics, Inc. 135 Beaver Street Waltham, MA 02452 To the Chairman of the Board of Directors: Effective as of the date hereof, I hereby resign my position as a member of the Board of Directors of lnterleukin Genetics, Inc., and as a member of all committees of such Board of Directors on which I serve. Sincerely, /s/ Goran Jurkov

WAIVER March 25, 2014

EX-99.7 Exhibit 99.7 WAIVER March 25, 2014 This Waiver is hereby given to Interleukin Genetics, Inc., a Delaware corporation (the “Company”), by Delta Dental Plan of Michigan, Inc., a Michigan nonprofit corporation and stockholder of the Company (“DDMI”). Reference is hereby made to that certain Common Stock Purchase Agreement, dated May 17, 2013, by and among the Company and the purchasers signat

ILIU / Interleukin Genetics, Inc. / Delta Dental Plan of Michigan, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Jonathan S. Groat Delta Dental Plan of Michigan, Inc. 4100 Okemos Road Okemos, MI 48864 (Name, Address

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2014 Interleukin Genetics, Inc.

INTERLEUKIN GENETICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

FOR IMMEDIATE RELEASE Contacts: Media: Investors: David Pitts Susan Kim Argot Partners Argot Partners 212-600-1902 212-600-1902 david@argotpartners.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

March 31, 2014

Exhibit 10.2 March 31, 2014 James M. Weaver Dear Jim: Interleukin Genetics, Inc. (the “Company”) is pleased to invite you to serve as the Chairman of the Company’s board of directors (the “Board”). If you accept this invitation, your membership on the Board will commence upon your formal election to the Board, which the Company expects to occur as soon as practicable following your acceptance. The

FIRST AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT

FIRST AMENDMENT TO THE COMMON STOCK PURCHASE AGREEMENT This First Amendment (the “Amendment”) to the Common Stock Purchase Agreement, dated May 17, 2013, by and among Interleukin Genetics, Inc.

Interleukin Genetics ANNUAL REPORT (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32715 INTERLEUKIN GENETICS, INC.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2014 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 v3679348k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 7, 2014 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0

Second Amendment to Commercial Lease

Exhibit 10.1 Second Amendment to Commercial Lease The Parties hereto, Clematis LLC, (“LESSOR”) and Interleukin Genetics, Inc., (“LESSEE”) are Parties under a certain Commercial Lease (“Lease Agreement”) dated February 13, 2004 and a First Amendment to Commercial Lease (“First Amendment”) dated November 18, 2008, for approximately 19,000 rentable square feet on the third floor at 135 Beaver Street,

ILIU / Interleukin Genetics, Inc. / Merlin BioMed Private Equity Advisors, L.L.C. - AMENDMENT NO. 1 Passive Investment

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Interleukin Genetics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 458738101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

INTERLEUKIN GENETICS INTRODUCES PERIOPREDICT™ Next-Generation Version of PST® Genetic Risk Test for Periodontal Disease Supported By Evidence from Recent Landmark Research Study

EX-99.1 2 v361744ex99-1.htm EXHIBIT 99.1 INTERLEUKIN GENETICS INTRODUCES PERIOPREDICT™ Next-Generation Version of PST® Genetic Risk Test for Periodontal Disease Supported By Evidence from Recent Landmark Research Study WALTHAM, Mass., – November 25, 2013 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the introduction of PerioPredict™, the Company’s new, next-generation version of the P

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 25, 2013 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2013 Interleukin Genetics, Inc.

ILIU / Interleukin Genetics, Inc. / Merlin BioMed Private Equity Advisors, L.L.C. - SCHEDULE 13G Passive Investment

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Interleukin Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 458738101 (CUSIP Number) May 17, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

INTERLEUKIN GENETICS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS

FOR IMMEDIATE RELEASE Contact: Interleukin Investors: Eliot Lurier, CFO Interleukin Genetics, Inc.

- FORM S-8

As filed with the Securities and Exchange Commission on August 14, 2013 Registration No.

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2013 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

INTERLEUKIN GENETICS, INC. 2013 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN

Exhibit 10.1 INTERLEUKIN GENETICS, INC. 2013 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Interleukin Genetics, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has d

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated August 9, 2013 120,408,197 SHARES OF COMMON STOCK This prospectus supplement supplements the prospectus dated August 9, 2013, relating to the offering and resale by the selling stockholders of up to 120,408,197 shares of our common stock. We will not receive any proceeds from the sale of th

CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION INTERLEUKIN GENETICS, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF INTERLEUKIN GENETICS, INC. It is hereby certified that: FIRST: The name of the corporation is Interleukin Genetics, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation filed with the Secretary of State of the State of Delaware on March 28, 2000, as amended to date, is hereby further amended by

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2013 Interleukin Genetics, Inc.

120,408,197 SHARES OF COMMON STOCK

Filed pursuant to Rule 424(b)(3) Registration No. 333-189749 PROSPECTUS 120,408,197 SHARES OF COMMON STOCK This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus or their pledgees, donees, transferees, or other successors in interest of up to 120,408,197 shares of our common stock. These shares consist of 85,326,230 issued and outstanding sha

-

INTERLEUKIN GENETICS, INC. 135 Beaver Street Waltham, Massachusetts 02452 August 7, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Austin Stephenson Re: Interleukin Genetics, Inc. Registration Statement on Form S-1 File No. 333-189749 Dear Mr. Stephenson: With respect to the above-referenced Registration Statem

-

Brian P. Keane | 617 348 3093 | [email protected] One Financial Center Boston, MA 02111 617-542-6000 617-542-2241 fax www.mintz.com July 26, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Filing Desk Re: Interleukin Genetics, Inc. Registration Statement on Form S-1 Filed July 1, 2013 File No. 333-189749 Ladies a

- AMENDMENT TO FORM S-1

As filed with the Securities and Exchange Commission on July 26, 2013 Registration Statement No.

Registration Statement - FORM S-1

As filed with the Securities and Exchange Commission on July 1, 2013 Registration Statement No.

- FORM DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

- FORM DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

- PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

CERTIFICATE OF ELIMINATION OF THE SERIES A-1 PREFERRED STOCK SERIES B PREFERRED STOCK INTERLEUKIN GENETICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware

EXHIBIT 3.1 CERTIFICATE OF ELIMINATION OF THE SERIES A-1 PREFERRED STOCK AND SERIES B PREFERRED STOCK OF INTERLEUKIN GENETICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Interleukin Genetics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) of the

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2013 Interleukin Genetics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 17) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

ILIU / Interleukin Genetics, Inc. / Delta Dental Plan of Michigan, Inc. - SCHEDULE 13D AMENDMENT NO. 1 Activist Investment

Schedule 13D Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Jonathan S. Groat Delta Dental Plan of Michigan, Inc. 4100 Okemos Road Okemos, MI

ILIU / Interleukin Genetics, Inc. / Growth Equity Opportunities Fund III, LLC - INTERLEUKIN GENETICS Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 458738101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, Ad

ILIU / Interleukin Genetics, Inc. / BAY CITY CAPITAL LLC - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Judy Koh Chief Financial Officer Bay City Capital LLC 750 Battery Street, Suite 400 San Francisco, CA 94111 (415)

JOINT FILING AGREEMENT

EX-99.1 2 d543022dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Each of Bay City Capital LLC, Bay City Capital Management V LLC, Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. hereby express its agreement that the attached Schedule 13D (and any amendments thereto) relating to the securities of Interleukin Genetics, Inc. is filed on behalf of each of them

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 17, 2013, between Interleukin Genetics, Inc., a Delaware corporation (the “Company”), each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”), Pyxis Innovations Inc., a Delaware corporation (“Pyxis”), De

COMMON STOCK PURCHASE WARRANT Interleukin Genetics, Inc.

EX-4.2 3 v345650ex4-2.htm EXHIBIT 4.2 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD E

VOTING AGREEMENT AND IRREVOCABLE PROXY

EX-10.3 6 v345650ex10-3.htm EXHIBIT 10.3 EXHIBIT 10.3 VOTING AGREEMENT AND IRREVOCABLE PROXY This Voting Agreement and Irrevocable Proxy (the “Agreement”) is made and entered into as of May 17, 2013, by and among Interleukin Genetics, Inc. a Delaware corporation (the “Company”), and Pyxis Innovations Inc., a Delaware corporation and a stockholder of the Company (“Pyxis”). RECITALS WHEREAS, concurr

INTERLEUKIN Genetics announces $12 million private placement

FOR IMMEDIATE RELEASE Contacts: Media: Investors: Jennifer Violette Eliot Lurier Public Relations Chief Financial Officer Interleukin Genetics, Inc.

COMMON STOCK PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. The Purchasers Identified on Schedule I Hereto May 17, 2013

Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT by and between Interleukin Genetics, Inc. and The Purchasers Identified on Schedule I Hereto May 17, 2013 Page 1. PURCHASE AND SALE 1 (a) Authorization of Shares 1 (b) Purchase of Shares and Warrant 1 2. CLOSINGS 1 (a) Initial Closing 1 (b) Subsequent Closings 2 (c) Form of Payment 3 (d) Conditions to the Purchaser’s Obligation to Purchase on the Initia

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 17, 2013 Interleukin Genetics, Inc.

COMMON STOCK PURCHASE WARRANT Interleukin Genetics, Inc.

EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 27, 2013 Interleukin Genetics, Inc.

Entry into a Material Definitive Agreement - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 25, 2013 Interleukin Genetics, Inc.

INTERLEUKIN GENETICS APPOINTS SCOTT SNYDER AS CHIEF MARKETING OFFICER

FOR IMMEDIATE RELEASE Contacts: Media: Investors: Jennifer Violette Eliot Lurier, CFO Interleukin Genetics, Inc.

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2013 Interleukin Genetics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2012 Interleukin Genetics, Inc.

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 16) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

AMENDED AND RESTATED PROMISSORY NOTE

AMENDED AND RESTATED PROMISSORY NOTE Date: November 30, 2012 $[original principal amount] Ada, Michigan FOR VALUE RECEIVED, the undersigned, INTERLEUKIN GENETICS, INC.

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 29, 2012 Interleukin Genetics, Inc.

FIFTH AMENDMENT AMENDED AND RESTATED NOTE PURCHASE AGREEMENT

FIFTH AMENDMENT TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT This FIFTH AMENDMENT TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT (the “Amendment”), dated and effective as of November 30, 2012, by and between INTERLEUKIN GENETICS, INC.

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT

EXHIBIT 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (the “Second Amendment”) to the Employment Agreement (the “Agreement”) dated as of November 12, 2008 by and between Interleukin Genetics, Inc., a Delaware corporation (“Employer”) and Kenneth S. Kornman, an individual (“Employee”), as amended by that certain First Amendment to Employment Agreement dated as of March 31, 201

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2012 Interleukin Genetics, Inc.

- REGISTRATION STATEMENT

S-8 1 v328380s-8.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on November 14, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Interleukin Genetics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of In

INTERLEUKIN GENETICS, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN

INTERLEUKIN GENETICS, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the 2012 Employee Stock Purchase Plan (the "Plan") of Interleukin Genetics, Inc. (the "Company"). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the intention of the Com

- FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2012 Interleukin Genetics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2012 Interleukin Genetics, Inc.

[Signature Page to Follow]

EX-10.1 2 v324141ex10-1.htm EXHIBIT 10.1 By Hand Delivery September 14, 2012 Lewis H. Bender Re: Separation Agreement Dear Lew: The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Interleukin Genetics, Inc. (“Interleukin” or the “Company”). Payment of the Separation Benefit described below is contingent on your agreement to and compliance with t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 23, 2012 Interleukin Genetics, Inc.

INTERLEUKIN Genetics ANNOUNCES EXECUTIVE MANAGEMENT CHANGES

Contacts: Media: Investors: Jennifer Violette Eliot Lurier Public Relations Chief Financial Officer Interleukin Genetics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 6, 2012 Interleukin Genetics, Inc.

Second annual dental cleaning does not reduce tooth loss in low risk patient population; High risk population benefits from additional care

Exhibit 99.1 UNIVERSITY OF MICHIGAN INFORMS INTERLEUKIN GENETICS OF STUDY RESULTS USING THE PST GENETIC TEST IN DETERMINING THE FREQUENCY OF DENTAL CLEANINGS 08/06/2012 Second annual dental cleaning does not reduce tooth loss in low risk patient population; High risk population benefits from additional care WALTHAM, Mass. – August 6, 2012 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today

CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION INTERLEUKIN GENETICS, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF INTERLEUKIN GENETICS, INC. It is hereby certified that: FIRST: The name of the corporation is Interleukin Genetics, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation filed with the Secretary of State of the State of Delaware on March 28, 2000, as amended to date, is hereby further amended by

ILIU / Interleukin Genetics, Inc. / PYXIS INNOVATIONS INC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 15) INTERLEUKIN GENETICS, INC. (Name of Issuer) Common Stock $.001 Par Value (Title of Class of Securities) 458738101 (CUSIP Number) Bryan Cave LLP One Metropolitan Square 211 North Broadway, Suite 3600 St. Louis, Missouri 63102 Attention: Robert J. Endico

ILIU / Interleukin Genetics, Inc. / Delta Dental Plan of Michigan, Inc. - SCHEDULE 13D Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Interleukin Genetics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 458738101 (CUSIP Number) Jonathan S. Groat Delta Dental Plan of Michigan, Inc. 4100 Okemos Road Okemos, MI 48864 (Name, Addres

THIRD AMENDMENT TO TO STOCK PURCHASE AGREEMENT

THIRD AMENDMENT TO TO STOCK PURCHASE AGREEMENT This THIRD AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is entered into as of this 29th day of June 2012, by and among Interleukin Genetics, Inc.

CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION INTERLEUKIN GENETICS, INC.

EX-3.1 2 v317506ex3-1.htm EXHIBIT 3.1 CORRECTED CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF INTERLEUKIN GENETICS, INC. Interleukin Genetics, Inc., a Delaware corporation (the “Corporation”), pursuant to Section 103(f) of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: That the Certificate of Amendment (the “Certificate of Amend

CERTIFICATE OF ELIMINATION OF THE SERIES A PREFERRED STOCK INTERLEUKIN GENETICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware

EX-3.2 3 v317506ex3-2.htm EXHIBIT 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES A PREFERRED STOCK OF INTERLEUKIN GENETICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Interleukin Genetics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) of the Delaw

FOURTH AMENDMENT AMENDED AND RESTATED NOTE PURCHASE AGREEMENT

FOURTH AMENDMENT TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT This FOURTH AMENDMENT TO AMENDED AND RESTATED NOTE PURCHASE AGREEMENT (the “Amendment”), dated and effective as of June 29, 2012, by and between INTERLEUKIN GENETICS, INC.

CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES A-1 PREFERRED STOCK AND SERIES B PREFERRED STOCK INTERLEUKIN GENETICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law)

EX-3.3 4 v317506ex3-3.htm EXHIBIT 3.3 CERTIFICATE OF DESIGNATIONS, PREFERENCES, AND RIGHTS OF SERIES A-1 PREFERRED STOCK AND SERIES B PREFERRED STOCK OF INTERLEUKIN GENETICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Interleukin Genetics, Inc., a Delaware corporation (the “Corporation”), hereby certifies that the following resolution was duly approved and adopted by th

AMENDED AND RESTATED PROMISSORY NOTE

EX-4.1 5 v317506ex4-1.htm EXHIBIT 4.1 AMENDED AND RESTATED PROMISSORY NOTE Date: June 29, 2012 $[original principal amount] Ada, Michigan FOR VALUE RECEIVED, the undersigned, INTERLEUKIN GENETICS, INC., a Delaware corporation, of 135 Beaver Street, 2nd Floor, Waltham, Massachusetts 02452 (the “Company”), promises to pay to PYXIS INNOVATIONS INC., a Delaware corporation, of 7575 Fulton Street East,

REGISTRATION RIGHTS AGREEMENT

Execution REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 29, 2012, is by and between INTERLEUKIN GENETICS, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2012 Interleukin Genetics, Inc.

EXCHANGE AGREEMENT

EXCHANGE AGREEMENT This Exchange Agreement (the “Agreement”) is entered into this 29th day of June, 2012 by and among Interleukin Genetics, Inc.